Physician profile
Robert Clark
NPI 1548249436
$2,401.45
in general payments reported to CMS, 2019-2025
20 companies · $130 in 2025
The $130 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $462 · 2020: $344 · 2021: $552 · 2022: $340 · 2023: $334 · 2024: $240 · 2025: $130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $704.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $704.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $830.93 | 2019-2025 | Skyrizi, Rinvoq |
| Sun Pharmaceutical Industries INC. | $260.36 | 2019-2023 | Ilumya |
| Ucb, INC. | $182.45 | 2019-2021 | |
| Janssen Biotech, INC. | $167.01 | 2019-2024 | Tremfya, Remicade, Stelara |
| Leo Pharma INC. | $163.69 | 2019-2023 | Adbry |
| Genzyme Corporation | $146.85 | 2019-2022 | |
| Lilly USA, LLC | $125.71 | 2021-2024 | Olumiant, Taltz, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $104.97 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $85.61 | 2019-2021 | |
| Amgen INC. | $62.75 | 2020-2022 | |
| Incyte Corporation | $49.72 | 2023 | Opzelura |
| Pfizer INC. | $37.64 | 2021-2025 | |
| Dusa Pharmaceuticals, INC. | $34.84 | 2019 | |
| Genentech USA, INC. | $33.73 | 2019-2020 | |
| Almirall LLC | $27.93 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $23.84 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.66 | 2022 | |
| Biofrontera INC. | $17.40 | 2019 | |
| Galderma Laboratories, L.P. | $16.06 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.